Table II.
Equilibrium and Peak Kinetic Solubility (mg/mL) in FaSSIF and FeSSIF
| Drug | Eq. FaSSIF sol. | Eq. FeSSIF sol. | Eq. FE ratio | Kinetic FaSSIF sol. | Kinetic FeSSIF sol. | Kinetic FE ratio | Human FE ratio | Correlates to human FE ratio | |
|---|---|---|---|---|---|---|---|---|---|
| Eq. sol. ratio | Kinetic sol. ratio | ||||||||
| BMS-B | 0.013 | 0.018 | 1.38 | 0.0115 | 0.0378 | 3.29 | 3.17 | Yes | Yes |
| BMS-C | 0.11 | 0.07 | 0.64 | 0.05 | 0.075 | 1.5 | 2.1 | No | Yes |
| BMS-D | 0.037 | 0.05 | 1.35 | 0.079 | 0.109 | 1.38 | 1.7 | Yes | Yes |
| BMS-E | 0.031 | 0.033 | 1.06 | 0.0479 | 0.0589 | 1.23 | 2.5 | No | Yes |
| BMS-M | 0.007 | 0.022 | 2.8 | 0.009 | 0.024 | 2.67 | 1.87 | Yes | Yes |
| BMS-N | 0.046 | 0.04 | 0.87 | 0.0463 | 0.0405 | 0.87 | 2.3 | No | No |
| BMS-P | 0.0002 | 0.003 | 15 | 0.01 | 0.059 | 5.9 | 3.7 | Yes | Yes |
| BMS-G | 0.023 | 0.002 | 0.08 | 0.105 | 0.108 | 1.03 | 1.2 | No | Yes |
| BMS-J | 0.095 | 0.892 | 9.39 | 0.036 | 0.0426 | 1.18 | 1.2 | No | yes |
Qualitative assessment of correlation to human FE based on human FE ratio categorization of positive FE (ratio >1.2); no FE (ratio 0.8–1.2); negative FE (ratio <0.8) as described in Table III